RxDoctor Payments Data

Laura Gaines

Family · Indiana, PANPI 1861092371

Payments from drug & device makers

$717in general payments, 2019–2025

Across 37 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$179
  • AbbVie$138
  • Novo Nordisk$98
  • Dexcom, Inc.$44
  • Lilly USA, LLC$37
  • Regeneron Healthcare Solutions, Inc.$35
  • plus $186 from 9 others

What the payments were for

  • Food & beverage$717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$717 in reported general payments places this provider in the 65th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$5,295
Medicare patients
38
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$35,127
JardianceEmpagliflozin38$28,280
EliquisApixaban13$13,359
MyrbetriqMirabegron22$12,286
Breo ElliptaFluticasone/Vilanterol14$10,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,863
Atorvastatin Calcium203$2,307
SynthroidLevothyroxine Sodium26$1,596
Tamsulosin Hcl61$1,179
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,069
Levothyroxine Sodium70$1,065
Omeprazole66$908
Metformin Hcl90$907
Rosuvastatin Calcium67$889
Lisinopril126$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$98$35,12738 claims
Boehringer IngelheimJardiance$21$28,28038 claims
GSKBreo Ellipta, Trelegy Ellipta$179$21,75425 claims
PfizerEliquis$30$13,35913 claims
Astellas Pharma US IncMyrbetriq$17$12,28622 claims
AbbVieSynthroid$138$1,59626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,717 family providers in Pennsylvania.

Other family in Indiana

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →